SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange📊Experiments🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge💹Economics📊Experiments🤖Agents🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision
biological_process

Amyloid-β Clearance

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about Amyloid-β Clearance: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

11Connections
18Hypotheses
7Analyses
2Outgoing
9Incoming
8Experiments
8Debates

Summary

The process by which amyloid-beta peptides are removed from the brain through enzymatic degradation (by neprilysin, insulin-degrading enzyme, BACE1 regulation), cellular phagocytosis by microglia, and transport across the blood-brain barrier via LRP1 and P-glycoprotein. Impaired clearance is a major contributor to amyloid plaque accumulation in Alzheimer's disease.

Ontology: GO:0097340 · MESH:D058031

No AI portrait yet

🧬 Biological Process Info
Nameamyloid clearance
Key Genes/ProteinsAPOE3, TREM2
Related Diseasesdisease progression
Linked Hypotheses20 hypotheses

Outgoing (2)

TargetRelationTypeStr
Disease Progressionmodulatesprocess0.85
disease progressioninhibitsdisease0.70

Incoming (9)

SourceRelationTypeStr
Donanemabpromotesdrug0.95
Donanemabpromotesdrug0.92
TREM2mediatesprotein0.90
Anti-Amyloid-beta Monoclonal Antibodiesmodulatesdrug0.90
TIM-3inhibitsprotein0.85

Targeting Hypotheses (18)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Closed-loop transcranial focused ultrasound to restore hippo 0.827 Alzheimer's disease Circuit-level neural dynamics in neurode
Test: TREM2 enhances amyloid clearance 0.755 - -
Test: TREM2 enhances amyloid clearance 0.712 - -
Test: TREM2 enhances amyloid clearance 0.705 - -
Test: TREM2 enhances amyloid clearance 0.655 - -
Test: TREM2 enhances amyloid clearance 0.637 - -
Test: TREM2 enhances amyloid clearance 0.612 - -
Closed-loop transcranial focused ultrasound to restore hippo 0.564 Alzheimer's disease Circuit-level neural dynamics in neurode
Test: TREM2 enhances amyloid clearance 0.555 - -
Test: TREM2 enhances amyloid clearance 0.537 - -
Test: TREM2 enhances amyloid clearance 0.512 - -
Test: TREM2 enhances amyloid clearance 0.437 - -
Test: TREM2 enhances amyloid clearance 0.405 - -
Test: TREM2 enhances amyloid clearance 0.400 - -
Test: TREM2 enhances amyloid clearance 0.400 - -
Test: TREM2 enhances amyloid clearance 0.400 - -
Test: TREM2 enhances amyloid clearance 0.400 - -
Test: TREM2 enhances amyloid clearance 0.400 - -

Mentioning Analyses (7)

Scientific analyses that reference this entity

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

neurodegeneration | 2026-04-16 | 0 hypotheses

How does HDAC1/2 deletion specifically enhance microglial amyloid phagocytosis c

neurodegeneration | 2026-04-13 | 2 hypotheses Top: 0.444

Is C1q elevation in AD pathogenic or compensatory for amyloid clearance?

neurodegeneration | 2026-04-12 | 0 hypotheses

Which specific metabolic pathways in APOE4+ microglia are most therapeutically t

neurodegeneration | 2026-04-08 | 0 hypotheses

Does SPP1-mediated synaptic engulfment represent beneficial clearance or patholo

synaptic biology | 2026-04-07 | 7 hypotheses Top: 0.708

Experiments (8)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
TREM2 KO amyloid pathology study validation Alzheimers Disease 0.750 0.00 Mouse (5xFAD/TREM2-/-) completed N/A
TREM2 KO amyloid pathology study validation Alzheimers Disease 0.750 0.00 Mouse (5xFAD/TREM2-/-) completed N/A
TREM2 KO amyloid pathology study validation Alzheimers Disease 0.750 0.00 Mouse (5xFAD/TREM2-/-) completed N/A
TREM2 KO amyloid pathology study validation Alzheimers Disease 0.750 0.00 Mouse (5xFAD/TREM2-/-) completed N/A
TREM2 KO amyloid pathology study validation Alzheimers Disease 0.750 0.00 Mouse (5xFAD/TREM2-/-) completed N/A
TREM2 KO amyloid pathology study validation Alzheimers Disease 0.750 0.00 Mouse (5xFAD/TREM2-/-) completed N/A
TREM2 KO amyloid pathology study validation Alzheimers Disease 0.750 0.00 Mouse (5xFAD/TREM2-/-) completed N/A
TREM2 KO amyloid pathology study validation Alzheimers Disease 0.750 0.00 Mouse (5xFAD/TREM2-/-) completed N/A

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (8)

Multi-agent debates referencing this entity

What are effective therapeutic strategies for targeting APOE4 in Alzheimer's dis

active · Rounds: 4 · Score: 0.82 · 2026-04-22

While SPP1 absence prevents synaptic loss, it's unclear whether this represents

active · Rounds: 4 · Score: 0.69 · 2026-04-21

What is the current clinical trial landscape for AD therapeutics, and which mech

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

Is the amyloid concentration in AD clinical trials rational given lecanemab's ap

closed · Rounds: 4 · Score: 0.39 · 2026-04-16

The debate revealed conflicting evidence about C1q's role - some studies show it

closed · Rounds: 4 · Score: 0.58 · 2026-04-16

While the study shows HDAC1/2 deletion improves amyloid clearance and cognition,

closed · Rounds: 4 · Score: 0.95 · 2026-04-13

While APOE4 disrupts microglial metabolism broadly, the debate didn't identify w

closed · Rounds: 4 · Score: 0.92 · 2026-04-09

APOE4 differs from APOE3 by C112R causing domain interaction that alters lipid b

closed · Rounds: 4 · Score: 0.89 · 2026-04-06

← Back to Knowledge Graph | Dashboard